Eastern Virginia Medical School, Virginia Beach, VA 23464, USA.
Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S10-4. doi: 10.1016/j.urolonc.2012.01.009.
Castrate resistant prostate cancer is a disease state which, counterintuitively, can be successfully treated with additional therapy directed at inhibition of androgen synthesis and/or interfering with the activity of the androgen receptor. Novel androgen biosynthesis inhibitors and antiandrogens are now being tested in large phase 3 clinical trials to clarify their role in the treatment of men who have failed traditional medical castration, with or without currently available nonsteroidal antiandrogens. A renewed interest in studying parenteral delivery of estrogens may provide evidence to revisit the initial medical therapy for advancing prostate cancer.
去势抵抗性前列腺癌是一种疾病状态，与常理相悖的是，通过额外的治疗抑制雄激素合成和/或干扰雄激素受体的活性，可以成功治疗这种疾病。目前正在大型 3 期临床试验中测试新型雄激素生物合成抑制剂和抗雄激素，以明确它们在治疗传统医学去势失败的男性中的作用，无论是否联合使用目前可用的非甾体类抗雄激素。重新研究雌激素的肠外给药可能提供证据，重新审视治疗进展期前列腺癌的初始医学疗法。
